With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Characterization of Novel OTX2-semaphorin Gene Signaling Pathways Regulating the ‘Grow and Go’ Arms of Highly Aggressive Medulloblastomas||University of Manitoba / Tamra Werbowetski-Ogilvie, PhD||Innovation Grants||2017||Manitoba|
|Role of Protocadherin-9 in Enabling Leukemia Cell Colonization of the CNS||National Jewish Health / Jordan Jacobelli, PhD||Innovation Grants||2017||Colorado|
|Cancer Susceptibility and Signaling Pathways in Low-Grade Brain Tumors||Jewish General Hospital / Bárbara Rivera, PhD||Young Investigator Grants||2017||Quebec|
|Development of Novel Biomarkers for Immunotherapy in Neuroblastoma||Columbia Institute for Cancer Genetics / Shuobo Boboila, PhD||Young Investigator Grants||2017||New York|
|A leukemia organoid platform for dissection and targeting of tumor-niche interactions||Columbia Institute for Cancer Genetics / Adolfo Ferrando, MD/PhD||Innovation Grants||2021||New York|
|Cell Line and Xenograft Repository||Texas Tech University Health Sciences Center / Patrick Reynolds, MD/PhD||Catalyst Grants||2014||Texas|
|Restoring RUNX1 Levels in FPD/AML||University of Washington, Seattle / Marshall Horwitz, MD/PhD||Familial RUNX1 Research Grants||2016||Washington|
|Identifying Therapeutic Targets to Prevent Progression of Familial RUNX1 Disorder to AML Using Novel iPSC Models||Icahn School of Medicine at Mount Sinai / Eirini Papapetrou, MD/PhD||Familial RUNX1 Research Grants||2016||New York|
|IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas||Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD||Reach Grants||2021||New York|
|DNA Methylation Inhibitor Therapy for Testicular Germ Cell Tumors||University of Illinois, Urbana-Champaign / Michael Spinella, Ph.D.||Reach Grants||2014||Illinois|